218 related articles for article (PubMed ID: 19715320)
21. Symplostatin 3, a new dolastatin 10 analogue from the marine cyanobacterium Symploca sp. VP452.
Luesch H; Yoshida WY; Moore RE; Paul VJ; Mooberry SL; Corbett TH
J Nat Prod; 2002 Jan; 65(1):16-20. PubMed ID: 11809057
[TBL] [Abstract][Full Text] [Related]
22. Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases.
Wieczerzak E; Drabik P; Łankiewicz L; Ołdziej S; Grzonka Z; Abrahamson M; Grubb A; Brömme D
J Med Chem; 2002 Sep; 45(19):4202-11. PubMed ID: 12213061
[TBL] [Abstract][Full Text] [Related]
23. Characterization of new fluorogenic substrates for the rapid and sensitive assay of cathepsin E and cathepsin D.
Yasuda Y; Kageyama T; Akamine A; Shibata M; Kominami E; Uchiyama Y; Yamamoto K
J Biochem; 1999 Jun; 125(6):1137-43. PubMed ID: 10348917
[TBL] [Abstract][Full Text] [Related]
24. Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F.
Frizler M; Schmitz J; Schulz-Fincke AC; Gütschow M
J Med Chem; 2012 Jun; 55(12):5982-6. PubMed ID: 22686657
[TBL] [Abstract][Full Text] [Related]
25. Crystal structure of an activation intermediate of cathepsin E.
Ostermann N; Gerhartz B; Worpenberg S; Trappe J; Eder J
J Mol Biol; 2004 Sep; 342(3):889-99. PubMed ID: 15342244
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of aspartic proteases by pepstatin and 3-methylstatine derivatives of pepstatin. Evidence for collected-substrate enzyme inhibition.
Rich DH; Bernatowicz MS; Agarwal NS; Kawai M; Salituro FG; Schmidt PG
Biochemistry; 1985 Jun; 24(13):3165-73. PubMed ID: 3927973
[TBL] [Abstract][Full Text] [Related]
27. Selection-by-function: efficient enrichment of cathepsin E inhibitors from a DNA library.
Naimuddin M; Kitamura K; Kinoshita Y; Honda-Takahashi Y; Murakami M; Ito M; Yamamoto K; Hanada K; Husimi Y; Nishigaki K
J Mol Recognit; 2007; 20(1):58-68. PubMed ID: 17173335
[TBL] [Abstract][Full Text] [Related]
28. A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.
Robichaud J; Oballa R; Prasit P; Falgueyret JP; Percival MD; Wesolowski G; Rodan SB; Kimmel D; Johnson C; Bryant C; Venkatraman S; Setti E; Mendonca R; Palmer JT
J Med Chem; 2003 Aug; 46(17):3709-27. PubMed ID: 12904076
[TBL] [Abstract][Full Text] [Related]
29. Dragonamides C and D, linear lipopeptides from the marine cyanobacterium brown Lyngbya polychroa.
Gunasekera SP; Ross C; Paul VJ; Matthew S; Luesch H
J Nat Prod; 2008 May; 71(5):887-90. PubMed ID: 18393465
[TBL] [Abstract][Full Text] [Related]
30. Tasiamide, a cytotoxic peptide from the marine cyanobacterium Symploca sp.
Williams PG; Yoshida WY; Moore RE; Paul VJ
J Nat Prod; 2002 Sep; 65(9):1336-9. PubMed ID: 12350160
[TBL] [Abstract][Full Text] [Related]
31. Probing of primed and unprimed sites of calpains: Design, synthesis and evaluation of epoxysuccinyl-peptide derivatives as selective inhibitors.
Dókus LE; Menyhárd DK; Tantos Á; Hudecz F; Bánóczi Z
Eur J Med Chem; 2014 Jul; 82():274-80. PubMed ID: 24915003
[TBL] [Abstract][Full Text] [Related]
32. The isolation and structure elucidation of Tasiamide B, a 4-amino-3-hydroxy-5-phenylpentanoic acid containing peptide from the marine Cyanobacterium Symploca sp.
Williams PG; Yoshida WY; Moore RE; Paul VJ
J Nat Prod; 2003 Jul; 66(7):1006-9. PubMed ID: 12880326
[TBL] [Abstract][Full Text] [Related]
33. Development of systemic in vitro evolution and its application to generation of peptide-aptamer-based inhibitors of cathepsin E.
Kitamura K; Yoshida C; Kinoshita Y; Kadowaki T; Takahashi Y; Tayama T; Kawakubo T; Naimuddin M; Salimullah M; Nemoto N; Hanada K; Husimi Y; Yamamoto K; Nishigaki K
J Mol Biol; 2009 Apr; 387(5):1186-98. PubMed ID: 19150354
[TBL] [Abstract][Full Text] [Related]
34. Antimalarial linear lipopeptides from a Panamanian strain of the marine cyanobacterium Lyngbya majuscula.
McPhail KL; Correa J; Linington RG; Gonzalez J; Ortega-Barría E; Capson TL; Gerwick WH
J Nat Prod; 2007 Jun; 70(6):984-8. PubMed ID: 17441769
[TBL] [Abstract][Full Text] [Related]
35. Micromide and guamamide: cytotoxic alkaloids from a species of the marine cyanobacterium Symploca.
Williams PG; Yoshida WY; Moore RE; Paul VJ
J Nat Prod; 2004 Jan; 67(1):49-53. PubMed ID: 14738385
[TBL] [Abstract][Full Text] [Related]
36. Cathepsins X and B can be differentiated through their respective mono- and dipeptidyl carboxypeptidase activities.
Therrien C; Lachance P; Sulea T; Purisima EO; Qi H; Ziomek E; Alvarez-Hernandez A; Roush WR; Ménard R
Biochemistry; 2001 Mar; 40(9):2702-11. PubMed ID: 11258881
[TBL] [Abstract][Full Text] [Related]
37. Cathepsin D inhibitors based on tasiamide B derivatives with cell membrane permeability.
Li Z; Li H; Jiang F; Wang Z; Zhang W
Bioorg Med Chem; 2022 Mar; 57():116646. PubMed ID: 35121401
[TBL] [Abstract][Full Text] [Related]
38. Specific cathepsin B inhibitor is cell-permeable and activates presentation of TTC in primary human dendritic cells.
Reich M; Wieczerzak E; Jankowska E; Palesch D; Boehm BO; Burster T
Immunol Lett; 2009 Apr; 123(2):155-9. PubMed ID: 19428564
[TBL] [Abstract][Full Text] [Related]
39. Aspartic cathepsin D degrades the cytosolic cysteine cathepsin inhibitor stefin B in the cells.
Železnik TZ; Kadin A; Turk V; Dolenc I
Biochem Biophys Res Commun; 2015 Sep; 465(2):213-7. PubMed ID: 26239660
[TBL] [Abstract][Full Text] [Related]
40. Procathepsin E is highly abundant but minimally active in pancreatic ductal adenocarcinoma tumors.
O'Donoghue AJ; Ivry SL; Chaudhury C; Hostetter DR; Hanahan D; Craik CS
Biol Chem; 2016 Sep; 397(9):871-81. PubMed ID: 27149201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
